Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial-Reference-Cited by-同舟云学术

Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial

Published:2013-12 Issue:13 Volume:14 Page:1317-1325
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Buzdar Aman U,Suman Vera J,Meric-Bernstam Funda,Leitch A Marilyn,Ellis Matthew J,Boughey Judy C,Unzeitig Gary,Royce Melanie,McCall Linda M,Ewer Michael S,Hunt Kelly K

Publisher

Elsevier BV

Subject

Oncology

Reference22 articles.

1. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18;Fisher;J Clin Oncol,1997

2. Preoperative chemotherapy treatment of breast cancer—a review;Buzdar;Cancer,2007

3. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease;Gralow;J Clin Oncol,2008

4. Pathological complete response and accelerated drug approval in early breast cancer;Prowell;N Engl J Med,2012

5. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes;von Minckwitz;J Clin Oncol,2012

Cited by 151 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling Neoadjuvant Therapy: Insights and Outlooks for HER2-Positive Early Breast Cancer;Current Treatment Options in Oncology;2024-08-17

2. Tailoring Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Recent Advances and Strategies;JCO Oncology Practice;2024-08

3. Concurrent epirubicin and trastuzumab use increases complete pathological response rate without additional cardiotoxicity in patients with human epidermal growth factor receptor 2‐positive early breast cancer: A meta‐regression analysis;Cancer Medicine;2024-07

4. iGenSig-Rx: an integral genomic signature based white-box tool for modeling cancer therapeutic responses using multi-omics data;BMC Bioinformatics;2024-06-19

5. Phytotherapeutics in Cancer: From Potential Drug Candidates to Clinical Translation;Current Topics in Medicinal Chemistry;2024-05